Email this article Results of non-medical switching from original infliximab to its Russian biosimilar in patients with ulcerative colitis
- Authors: Timanovskaia M.I.1, Knyzev O.V.1, Parfenov A.I.1
-
Affiliations:
- Loginov Moscow Clinical Scientific Center
- Issue: Vol 97, No 2 (2025): Вопросы гастроэнтерологии
- Pages: 145-148
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/291019
- DOI: https://doi.org/10.26442/00403660.2025.02.203184
- ID: 291019
Cite item
Full Text
Abstract
Aim. To evaluate the efficacy and safety of the Russian biosimilar infliximab in patients with ulcerative colitis (UC).
Materials and methods. This is a retrospective study of stable patients with UC, who are followed up at the department of bowel pathology of Loginov Moscow Clinical Scientific Center and who underwent a non-medical switch from the original infliximab to its Russian biosimilar. The primary outcome is treatment continuation for 16 weeks after the switch. Secondary outcomes include the rate of loss of response, adverse events, and immunogenicity during the first 12 months after the switch.
Results. There was no significant difference in infliximab continuation between the biosimilar, switch and control groups. While the alternation group had the highest rate of loss of response and adverse events.
Conclusion. Non-medical switching from the original infliximab to its Russian biosimilar, as well as therapy with a biosimilar under one trade name, demonstrates similar clinical results compared to continuing to take the original molecule for the treatment of UC. The obtained data confirm the safety and efficacy of non-medical switching to infliximab in patients with UC.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Maria I. Timanovskaia
Loginov Moscow Clinical Scientific Center
Author for correspondence.
Email: zwmr306@mail.ru
ORCID iD: 0000-0002-7937-2346
мл. науч. сотр. отд-ния воспалительных заболеваний кишечника
Russian Federation, MoscowOleg V. Knyzev
Loginov Moscow Clinical Scientific Center
Email: zwmr306@mail.ru
ORCID iD: 0000-0001-7250-0977
д-р мед. наук, зав. отд-нием воспалительных заболеваний кишечника
Russian Federation, MoscowAsfold I. Parfenov
Loginov Moscow Clinical Scientific Center
Email: zwmr306@mail.ru
ORCID iD: 0000-0002-9782-4860
д-р мед. наук, проф., рук. отд. патологии кишечника
Russian Federation, MoscowReferences
- Park SH, Park JC, Lukas M, et al. Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases. Intest Res. 2020;18(1):34-44. doi: 10.5217/ir.2019.09147
- Guidance for industry: quality considerations in demonstrating biosimilarity to a therapeutic protein product to a reference product. Available at: https://www.fda.gov/downloads/drugs/guidances/ucm291134.pdf. Accessed: 12.01.2020.
- Chang S, Hanauer S. Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2017;15(1):53-70. doi: 10.1007/s11938-017-0122-6
- FDA approves Inflectra, a biosimilar to Remicade. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm494227.htm. Accessed: 12.01.2020.
- Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605-12. doi: 10.1136/annrheumdis-2012-203091
- Danese S, Fiorino G, Raine T, et al. ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update. J Crohns Colitis. 2017;11(1):26-34. doi: 10.1093/ecco-jcc/jjw198
- AGA makes six recommendations to FDA on interchangeable biosimilars. Available at: http://www.gastro.org/news_items/aga-makes-six-recommendations-to-fda-on-interchangeable-biosimilars. Accessed: 12.01.2020.
Supplementary files
